Quarterly ResultMay 7, 2026, 04:42 PM
Vera Therapeutics Q1 Net Loss Widens to $121.0M
AI Summary
Vera Therapeutics reported a significant increase in net loss for the first quarter of 2026, reaching $121.0 million, compared to $51.7 million in the same period of 2025. This was primarily driven by a substantial rise in research and development and general and administrative expenses. While cash and cash equivalents decreased, marketable securities increased, bringing total liquidity to $596.8 million, which management believes is sufficient for at least the next 12 months. The company continues to incur net operating losses and expects to raise additional capital to fund its long-term objectives.
Key Highlights
- Net loss widened to $121.0 million in Q1 2026 from $51.7 million in Q1 2025.
- Net loss per share was $(1.69) in Q1 2026, up from $(0.81) in Q1 2025.
- Research and development expenses increased to $86.0 million from $41.3 million.
- General and administrative expenses rose to $39.1 million from $15.9 million.
- Cash and cash equivalents decreased to $114.4 million from $354.7 million.
- Marketable securities increased to $482.4 million from $359.9 million.
- Total cash, cash equivalents, and marketable securities were $596.8 million.
- Accumulated deficit reached $881.9 million as of March 31, 2026.